Merck & Co., Inc. $MRK Stock Position Raised by Hamilton Wealth LLC

Hamilton Wealth LLC increased its position in Merck & Co., Inc. (NYSE:MRK) by 99.6% in the third quarter, HoldingsChannel reports. The firm owned 116,753 shares of the company’s stock after acquiring an additional 58,271 shares during the period. Merck & Co., Inc. accounts for about 2.0% of Hamilton Wealth LLC’s investment portfolio, making the stock its 13th biggest holding. Hamilton Wealth LLC’s holdings in Merck & Co., Inc. were worth $9,799,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. One Charles Private Wealth Services LLC lifted its holdings in shares of Merck & Co., Inc. by 3.3% in the third quarter. One Charles Private Wealth Services LLC now owns 3,464 shares of the company’s stock valued at $291,000 after purchasing an additional 111 shares in the last quarter. Dakota Community Bank & Trust NA grew its holdings in shares of Merck & Co., Inc. by 3.4% during the third quarter. Dakota Community Bank & Trust NA now owns 3,566 shares of the company’s stock valued at $299,000 after buying an additional 116 shares in the last quarter. Security National Bank of Sioux City Iowa IA grew its holdings in shares of Merck & Co., Inc. by 3.6% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 3,402 shares of the company’s stock valued at $286,000 after buying an additional 119 shares in the last quarter. Investors Research Corp raised its position in Merck & Co., Inc. by 1.3% during the third quarter. Investors Research Corp now owns 9,325 shares of the company’s stock valued at $783,000 after buying an additional 120 shares during the period. Finally, Trust Point Inc. raised its position in Merck & Co., Inc. by 0.8% during the third quarter. Trust Point Inc. now owns 14,834 shares of the company’s stock valued at $1,245,000 after buying an additional 120 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MRK. Cantor Fitzgerald raised their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Guggenheim upped their target price on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a report on Friday, February 6th. Bank of America increased their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Barclays started coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They set an “overweight” rating and a $140.00 price target for the company. Finally, Zacks Research lowered shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $126.81.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, CFO Caroline Litchfield sold 41,997 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the sale, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at $10,787,865.12. The trade was a 31.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CMO Chirfi Guindo sold 20,000 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the transaction, the chief marketing officer owned 80,615 shares in the company, valued at approximately $9,825,356.20. This trade represents a 19.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 320,176 shares of company stock valued at $38,281,735 in the last ninety days. 0.09% of the stock is currently owned by insiders.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $115.61 on Monday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The business’s 50-day moving average price is $115.26 and its two-hundred day moving average price is $99.79. The company has a market capitalization of $285.84 billion, a P/E ratio of 15.88, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same period in the prior year, the firm posted $1.72 EPS. The business’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be issued a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.